Core Scientific Quarterly Income Statement
NASDAQ: CORZFinanceFinance: Consumer ServicesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Core Scientific revenue and earnings
In the quarter ended Jun 30, 2026, Core Scientific generated $164.2 million in revenue, up 108.8% from the same quarter a year earlier. Core Scientific reported a net loss of $1.16 billion, compared with a loss of $936.8 million a year earlier. Gross margin was 42.7% (up from 6.4%) and operating margin -47.8%.
Diluted earnings per share came in at -$3.32.
Summary generated from market data by MetaCap's automated system. Methodology
Core Scientific income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 164.20M | 115.24M | 79.76M | 81.10M | 78.63M | 79.53M | 94.92M | 95.35M | 141.10M | 179.29M | 141.93M | 112.90M |
| Revenue growth (YoY) | +108.83% | +44.92% | -15.97% | -14.95% | -44.28% | -55.64% | -33.12% | -15.54% | +11.18% | +48.60% | +17.05% | -30.55% |
| Cost of Revenue | 94.16M | 85.14M | 59.01M | 77.20M | 73.60M | 71.31M | 90.16M | 95.51M | 102.28M | 101.64M | 102.63M | 97.48M |
| Gross Profit | 70.04M | 30.11M | 20.75M | 3.90M | 5.03M | 8.21M | 4.76M | -156.00K | 38.82M | 77.65M | 39.30M | 15.42M |
| Operating Expenses | 148.51M | 340.53M | 138.23M | 58.70M | 31.31M | 55.25M | 70.15M | 41.06M | 129.50M | 22.42M | 35.37M | 27.46M |
| Research & Development | — | — | — | — | — | — | 5.02M | 2.84M | 2.17M | 1.80M | 1.88M | 2.25M |
| Selling, General & Admin | 49.39M | 44.85M | -11.63M | 69.35M | 45.28M | 32.29M | 25.04M | 40.35M | 31.38M | 16.92M | 28.12M | 24.55M |
| Operating Income | -78.47M | -310.42M | -117.47M | -54.79M | -26.28M | -47.04M | -65.39M | -41.22M | -90.68M | 55.23M | 3.93M | -12.04M |
| Interest Expense | 40.65M | 8.16M | — | — | 4.75M | 4.75M | — | — | — | — | — | — |
| Other Income (Expense) | -1.07B | -36.17M | 333.53M | -89.11M | -910.36M | 623.49M | -225.38M | -413.91M | -811.33M | 155.67M | -199.29M | -28.99M |
| Pretax Income | -1.15B | -346.59M | 216.05M | -143.90M | -936.64M | 576.46M | -290.77M | -455.13M | -902.01M | 210.90M | -195.36M | -41.03M |
| Income Tax | 1.91M | 600.00K | 95.00K | 125.00K | 158.00K | 205.00K | 375.00K | 134.00K | 144.00K | 206.00K | 336.00K | 114.00K |
| Net Income | -1.16B | -347.19M | 215.96M | -144.03M | -936.80M | 576.25M | -291.15M | -455.26M | -902.16M | 210.69M | -195.69M | -41.15M |
| Net Income growth (YoY) | — | -160.25% | — | — | — | +173.51% | — | — | — | — | — | — |
| EPS (Basic) | -3.32 | -1.06 | -1.81 | -0.45 | -0.04 | 1.42 | -0.69 | -1.17 | -5.05 | 0.91 | -0.52 | -0.11 |
| EPS (Diluted) | -3.32 | -1.06 | -1.63 | -0.45 | -0.04 | 1.24 | -0.69 | -1.17 | -5.05 | 0.78 | -0.52 | -0.11 |
| Shares Outstanding (Basic) | 325.33M | 322.91M | — | 318.56M | 317.99M | 315.19M | — | 292.49M | 178.50M | 230.95M | — | 382.48M |
| Shares Outstanding (Diluted) | 325.33M | 322.91M | — | 318.56M | 317.99M | 363.31M | — | 292.49M | 178.50M | 282.53M | — | 382.48M |
| EBITDA | -62.97M | -293.77M | -103.38M | -38.46M | -7.53M | -27.31M | -39.35M | -12.53M | -61.20M | 84.22M | 35.14M | 12.19M |
| Gross Margin | 42.66% | 26.12% | 26.02% | 4.81% | 6.39% | 10.33% | 5.02% | -16.00% | 27.51% | 43.31% | 27.69% | 13.66% |
| Operating Margin | -47.79% | -269.36% | -147.28% | -67.56% | -33.43% | -59.15% | -68.89% | -43.23% | -64.27% | 30.80% | 2.77% | -10.67% |
| Net Margin | -703.59% | -301.26% | 270.75% | -177.59% | -1191.43% | 724.62% | -306.71% | -477.44% | -639.37% | 117.51% | -137.88% | -36.44% |
This table shows 12 quarterly periods of Core Scientific's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow CORZ's reporting calendar. What is a income statement?